STOCK TITAN

MEI Pharma Announces Acceptance of Two Abstracts for Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2022

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

MEI Pharma, Inc. (NASDAQ: MEIP) has announced that two abstracts will be presented at the American Association for Cancer Research Annual Meeting 2022 from April 8-13, 2022. The first abstract concerns zandelisib (ME-401) in chronic lymphocytic leukemia, showing promising immunomodulatory effects and improved survival in preclinical models. The second abstract discusses ME-344, combined with venetoclax, demonstrating a new approach to overcome treatment resistance in acute myeloid leukemia. These developments highlight MEI Pharma's commitment to advancing cancer therapies.

Positive
  • Presentation of two abstracts at a prominent cancer research conference.
  • Zandelisib shows immunomodulatory effects, decreasing suppressive markers in CLL.
  • ME-344 combined with venetoclax offers a novel approach to treat resistant AML.
Negative
  • None.

SAN DIEGO--(BUSINESS WIRE)-- MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that two abstracts highlighting data from two oncology drug candidates in its pipeline will be presented at the upcoming American Association for Cancer Research Annual Meeting 2022 to be held April 8 – 13, 2022.

Details of the poster presentations:

Title: Efficacy and immune profiling of the PI3K delta inhibitor zandelisib (ME-401) in a preclinical model of chronic lymphocytic leukemia (CLL)
Authors: Dr. Maharaj, et. al.
Date: Friday, April 8, 2022, 8:30 AM ET
Abstract ID: 5496

Summary of results: data from preclinical studies with zandelisib ex vivo in normal human T cells and in vivo in a murine CLL model suggest that zandelisib has immunomodulatory properties on human T cells including decreased activation and expression of suppressive markers such as PD-1 and CTLA-4 on inducible regulatory (Tregs) and CD4+ T cells. In the murine CLL model, a reduction in Treg numbers, markers of terminal memory differentiation and T-cell exhaustion on CD4+ and CD8+ T cells, as well as improvement in overall survival was observed.

Title: ME-344, a novel isoflavone mitochondrial inhibitor, in combination with venetoclax constitutes a new metabolism-targeted approach to overcome resistance to Bcl-2 inhibition and standard of care treatment in AML
Authors: Katie Hurrish, et. al.
Date: Wednesday, April 13, 2022, 10:00 AM1:30 PM ET
Abstract ID: 3785

Summary of results: data from in vitro and in vivo preclinical studies evaluating the combination of ME-344 with venetoclax in standard-of-care-resistant acute myeloid leukemia (AML) cell lines and relapsed or refractory (R/R) AML patient samples suggest that ME-344, both alone and in combination with venetoclax, inhibits purine biosynthesis, suppresses oxidative phosphorylation, induces apoptosis and decreases Mcl-1, which together target metabolic vulnerabilities of AML cells.

About MEI Pharma

MEI Pharma, Inc. (Nasdaq: MEIP) is a late-stage pharmaceutical company focused on developing potential new therapies for cancer. MEI Pharma's portfolio of drug candidates contains multiple clinical-stage assets, including zandelisib, currently in ongoing clinical trials which may support marketing approvals with the U.S. Food and Drug Administration and other regulatory authorities globally. Each of MEI Pharma's pipeline candidates leverages a different mechanism of action with the objective of developing therapeutic options that are: (1) differentiated, (2) address unmet medical needs and (3) deliver improved benefit to patients either as standalone treatments or in combination with other therapeutic options. For more information, please visit www.meipharma.com. Follow us on Twitter @MEI_Pharma and on LinkedIn.

Forward-Looking Statements

Under U.S. law, a new drug cannot be marketed until it has been investigated in clinical studies and approved by the FDA as being safe and effective for the intended use. Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. You should be aware that our actual results could differ materially from those contained in the forward-looking statements, which are based on management's current expectations and are subject to a number of risks and uncertainties, including, but not limited to, our failure to successfully commercialize our product candidates; the availability or appropriateness of utilizing the FDA’s accelerated approval pathway for our product candidates; final data from our pre-clinical studies and completed clinical trials may differ materially from reported interim data from ongoing studies and trials; costs and delays in the development and/ or FDA approval, or the failure to obtain such approval, of our product candidates; uncertainties or differences in interpretation in clinical trial results; the impact of the COVID-19 pandemic on our industry and individual companies, including on our counterparties, the supply chain, the execution of our clinical development programs, our access to financing and the allocation of government resources; our inability to maintain or enter into, and the risks resulting from our dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales and distribution of any products; competitive factors; our inability to protect our patents or proprietary rights and obtain necessary rights to third party patents and intellectual property to operate our business; our inability to operate our business without infringing the patents and proprietary rights of others; general economic conditions; the failure of any products to gain market acceptance; our inability to obtain any additional required financing; technological changes; government regulation; changes in industry practice; and one-time events. We do not intend to update any of these factors or to publicly announce the results of any revisions to these forward-looking statements.

MEI Pharma Contacts

David A. Walsey

MEI Pharma

Tel: 858-369-7104

investor@meipharma.com

Jason I. Spark

Canale Communications for MEI

Tel: 619-849-6005

jason.spark@canalecomm.com

Source: MEI Pharma, Inc.

FAQ

What abstracts will MEI Pharma present at the American Association for Cancer Research Annual Meeting 2022?

MEI Pharma will present two abstracts: one on zandelisib (ME-401) for chronic lymphocytic leukemia and another on ME-344 in combination with venetoclax for acute myeloid leukemia.

When is the American Association for Cancer Research Annual Meeting 2022?

The American Association for Cancer Research Annual Meeting 2022 will be held from April 8 to April 13, 2022.

What are the key findings of the zandelisib study presented by MEI Pharma?

The zandelisib study shows immunomodulatory properties with a reduction in suppressive markers and improved overall survival in a preclinical model.

How does ME-344 work in combination with venetoclax?

ME-344, combined with venetoclax, inhibits purine biosynthesis and targets metabolic vulnerabilities in acute myeloid leukemia cells, helping overcome treatment resistance.

MEI Pharma, Inc.

NASDAQ:MEIP

MEIP Rankings

MEIP Latest News

MEIP Stock Data

16.33M
6.58M
1.31%
41.04%
1.22%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
SAN DIEGO